A prospective, randomized, controlled clinical study of Huai Qi Huang granules in treatment of childhood primary nephrotic syndrome.
- Author:
Hai-Yun GENG
1
;
Li CAO
;
Wei WANG
;
Da-Kun CHEN
;
Chao-Ying CHEN
;
Mei CHU
;
Li-Na JI
;
Jing-Jing WANG
;
Juan TU
;
Jian-Guo LI
;
Hua-Rong LI
;
Pei-Wei DU
Author Information
- Publication Type:Journal Article
- MeSH: Astragalus membranaceus; Child; Child, Preschool; Drugs, Chinese Herbal; therapeutic use; Female; Glucocorticoids; therapeutic use; Humans; Infant; Male; Nephrotic Syndrome; drug therapy; Prospective Studies
- From: Chinese Journal of Contemporary Pediatrics 2015;17(1):31-34
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the efficacy of Huai Qi Huang granules in the treatment of childhood primary nephrotic syndrome.
METHODSBetween July 2009 and December 2011, patients who were admitted and diagnosed for the first time as childhood primary nephrotic syndrome were randomized into a treatment group (Huai Qi Huang granules plus glucocorticoid; n=23) and a control group (glucocorticoid alone; n=19) for a prospective study. The two groups were compared for regression time of edema, time to urinary protein clearance, relapse rate, incidence of infection, dosage of glucocorticoid, and humoral and cellular immunological indicators.
RESULTSThere were no significant differences in regression time of edema, time to urinary protein clearance, and relapse rate between the treatment and control groups (P>0.05). The treatment group had significantly lower incidence of infection and daily dose of glucocorticoid (at month 6) than the control group (P<0.05). Humoral and cellular immunological indicators showed no significant differences between the two groups (P>0.05). No Huai Qi Huang-related adverse events were observed in this study.
CONCLUSIONSHuai Qi Huang granules treatment can reduce the dose of glucocorticoid and the incidence of infection in children with primary nephrotic syndrome and has a favourable safety.
